Conferred prestigious award at event ABP News Presents Healthcare Leadership Awards 26th November, 2018 at Taj Lands End, Mumbai India
Dedicated to Shobha Crasto Aishal crasto Lionel crasto
Service to education is service to humanity
Society recognises efforts done towards it
/////////////award, event ABP News, Healthcare, Leadership, 26th, November, 2018, Taj Lands End, Mumbai, India, education, anthony crasto
////////////National award, contribution to Pharma society, Times Network, Excellence in HEALTHCARE, 5th July, 2018, Taj Lands End, Mumbai, India, ANTHONY CRASTO
#hotpersoninawheelchair
#worlddrugtracker
Scientific Update, UK, Course on ‘Chemical Development & Scale Up in the Pharmaceutical Industry’, Sea Princess Hotel, Mumbai, India, 6th – 8th February 2017
Want to download Brochure click View Brochure 
6-8 FEB 2017
A PRESENTATION BROCHURE
The presentation will load below
6-8 FEB 2017
PLEASE SCROLL WITH MOUSE TO VIEW BROCHURE
Want to download Brochure click : View Brochure 6-8 FEB 2017
Scientific Update, UK, Course on ‘Chemical Development & Scale Up in the Pharmaceutical Industry’, Sea Princess Hotel, Mumbai, India, 6th – 8th February 2017……..Chemical process development is generally not taught as part of degree courses in higher education; the conversion of a synthetic route used for making milligram or gram quantities of a chemical into a process for manufacturing multi-kilogram and tonne quantities is typically learnt “on the job” by chemists in industry. For many years, little chemical development work was published in the literature, until the establishment of the Organic Process R & D journal by Dr Trevor Laird (Founder of Scientific Update). Even now, “tricks of the trade” are handed down within individual company organisations, and it can be difficult to gain an awareness of what is involved in chemical development, and of the skills and techniques required to efficiently scale up chemical processes.
This three-day course, written and presented by highly experienced process chemists from the pharmaceutical and fine chemical industry, provides a comprehensive overview of this fascinating and important element of the chemical industry. A logical investigative approach to all aspects of chemical development is described, with an abundance of case studies from literature, conferences and private communications. The multi-disciplinary nature of chemical development is emphasised, from the initial interaction with laboratory research scientists to the vital partnership with chemical engineers in the pilot plant and in the production environment. The lectures are interspersed with interactive problem sessions, enabling participants to share in the problem solving and troubleshooting typically experienced during chemical development.
Want to download Brochure click View Brochure 6-8 FEB 2017
Title:Chemical Development & Scale-Up in the Fine Chemical & Pharmaceutical Industries
Subtitle:Principles and Practice
When:06.02.2017 – 08.02.2017
Tutors:
Where:The Sea Princess Hotel – MumbaiBrochure View Brochure 6-8 FEB 2017
see a presentation above
DESCRIPTION
Kind regards,
Dr Claire Francis
Director
Scientific Update Ltd, Maycroft Place
Stone Cross, Mayfield, East Sussex
TN20 6EW, UK
T: +44 (0) 1435 873062
E: claire@scientificupdate.co.uk
Want to download Brochure click :View Brochure 6-8 FEB 2017
//////////course, scientific update, sea princess, mumbai, india, claire francis, will watson, helen, john knight, Chemical Development , Scale, Pharmaceutical Industry, uk, feb
1st December 2016, Kohinoor Continental Hotel, Mumbai, India
After the successful journey of a series of 10 Pharmacovigilance conferences, Virtue Insight is proud to announce its 11th Pharmacovigilance 2016 in India. It is our great pleasure to invite you to the 11th Pharmacovigilance 2016, in Mumbai – India on 1st of December 2016. We have a wide range of scientific topics with something for everyone.
The past is reflected in a session about Indian traditional medicine and the future is discussed under Big Data analytics and in the research of our young scientists. However, we must live and act in the present and debate pressing challenges that face us today in pharmacovigilance (PV). The rates for medication errors are too high. We still struggle to communicate risk well. With the welcome drive towards transparency and respecting human rights, legal and ethical issues in PV have come to the fore. Society’s research enterprise as a whole needs to become far more aware of the commercial reality that PV underpins safety, with its intimate links to innovation, so that safety and must be intrinsically built into successful development and marketing. With governments round the world struggling to curb healthcare costs, the importance of integrating PV into National Health Programmes has never been more important.
It gives me great pleasure in welcoming all of you to the virtue insight’s 11th Pharmacovigilance 2016. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.
pic KANCHI SHAH, VIRTUEINSIGHT
|
|||||||||||||||||||||
Plus Many More..
Vice Presidents, Directors, CRO’s, Heads and Managers of:
Pharmacovigilance Strategy, Drug Safety/Risk Management, Information and Clinical Data Management, Clinical Research, Research & Development, Product Safety/Assurance Assessment, Patient Safety & Outcomes Research & Data Analysis, Epidemiology project management, Regulatory Affairs and Compliance, Sales & Marketing, Biotech manufacturers
Pharmaceutical organizations, Generic pharmaceutical companies, Contract research organizations, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants
This event also serves as a platform for networking opportunities in the relevant field , wherein you get to meet and broaden your contacts to develop your business. We also have sponsorship opportunities available for the event which gives you an opportunity to speak/exhibit and create brand awareness. Or you could even attend the event as a delegate and get a better insight of the updates and the increasing challenges in the industry . So hurry now and be a part of this massive event.
GLIMPSES OF MY( DR ANTHONY) INTERACTION
with Fen Castro of VirtueInsight, Director , and his team , , —thanks for inviting me to 9th Biosimilars Congregation 2016., Lalit hotel, Mumbai, India, 22nd Sept 2016 — with Fen Castro, Kanchi Shahand Virtue Insight at The Lalit Hotel.
CONFERENCE BOOKING DETAILS
| Online Registration http://www.bookmytrainings. |
| Early Bird Discount Price – 1 Delegate Pass (INR 6,000 + Tax (15%) – Book and Pay before 17th October 2016 to avail this price |
| Standard Price (From 18th October 2016) – 1 Delegate Pass – (INR 7,000 + Tax (15%) |
| Group Discounts (Applicable for 3 or 4) – 1 Delegate Pass – (INR 6,500 + Tax (15%) |
| Group Discounts (Applicable for 5 or more) – 1 Delegate Pass – (INR 6,000 + Tax (15%) |
| Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, Exhibition Stall (Booth) or a paid Speaker Slot, you can simply call or email your interest and queries to TEL: +91 44 64614333, or sponsor@virtueinsight.com |
In order to register simply email the below mentioned details to delegate@virtueinsight.com
We also have some sponsorship opportunities available for the event, which gives you an opportunity to speak/exhibit, and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.
In case you or any of your colleagues might be interested in participating in the same, please let us know and we will be happy to call you and help you with the registration.
SEE BROCHURE
ALLOW BROCHURE TO LOAD
Thank you for your time and consideration.
Fen Castro
Head – Productions
Virtue Insight
Tel (India) – + 91 44 64614333
Mobile (India) – + 91 9003 26 0693
Tel (UK) – + 44 2036120886
////////////11th Pharmacovigilance, 2016, 1st Dec, 2016, Kohinoor Continental Hotel, Mumbai, India, Conference, fen castro
India's only conference focusing on new chiral technologies for pharmaceutical fine chemicals. The event is a unique platform to learn about recent advances in chiral chemistry, technology and application.
Chiral India series which began in 2012 has now grown into a major must-attend event for the Pharmaceutical industry. This platform is the most popular chiral technology platform bringing together the top experts from China, Canada, USA, Japan, India and other countries to present the latest developments in chiral drug developments and brainstorm with leading R&D personnel from Indian pharmaceutical industry.
The fifth edition of Chiral India to be held on 8-9 November 2016, at Holiday Inn (Mumbai), follows the success of previous four annual editions (2012, 2013, 2014 and 2015) and is now an event awaited by R&D professionals across the industry.
|
||||||||||||
R Rajagopal
+9198211 28341
rraj@chemicalweekly.com
kiran@chemicalweekly.com
| Dr. R. Rajagopal | B-602, Godrej Coliseum | Tel: +91 22 24044477 |
| Editorial Advisor | K.J. Somaiya Hospital Road | Fax: +91 22 24044450 |
| Chemical Weekly | Sion (East) Mumbai 400 022 | www.chemicalweekly.com |
DOWNLOAD BROCHURE…..
Please use http://www.chiralindia.com/Brochure.pdf link to download the Brochure.
Our website URL is www.chiralindia.com
|
Oganised By
|
 |
SCROLL USING MOUSE TO VIEW 5 PAGES
////////CHIRAL INDIA 2016, 5th International Conference, Exhibition, Nov 8-9, 2016, Holiday Inn, Mumbai, India
Innogen summit India 2016, 18-19 Aug, Mumbai, India, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd………topic is Supergenerics, Innovation in Generics, commercialization, regulatory, other insights,
Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd, at Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — with DR ASHOK KUMAR OF IPCA at Holiday Inn-Mumbai Intl Airport.
PANEL DISCUSSION, Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd , Dr. Nilima A. Kshirsagar, National Chair Clinical Pharmacology, ICMR Government of India, Yugal Sikri, Chairman – Pharmaceutical Management, School of Business Management, SVKM’s Narsee Monjee Institute of Management Studies — with Yugal Sikri,, Nilima A. Kshirsagarand ASHOK KUMAR OF IPCA at Holiday Inn-Mumbai Intl Airport.
Ashit sikka, Koji nakamura, Uttam kumar, allfdron TERUMO, AT Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — with Koji nakamura of terumo, Ashit Sikka and UTTAM KUMAR OF TERUMO at Holiday Inn-Mumbai Intl Airport.
ROHAN, RIDDHI AND PALLAVI OF INVENTICON
DR NIDHI SAPKAL OF ZIMLABS
ALKA LUTHRA OF LUBRIZOL
DR SEEMA SINGH, VP AND HEAD,-LEGAL AND IPM, MACLOEDS PHARMA, Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — withSeema Singh.
standing Mr Rajeev patil, Sr VP reg affairs Lupin and Mr Sushrut kulkarni Sr VP Zydus cadila, Head, Pharma tech cemtre — with sushrut kulkarni andrajeev patil.
Thanks to
Rohan Jagtap
Program Manager – Pharma & Lifesciences
Inventicon Business Intelligence Pvt. Ltd.
Phone: +91 22 6511 3334 I Mob: +91 9011052025 Email: rohan.jagtap@inventiconasia.
Times Square, Unit 1, Level 2, B Wing, Andheri Kurla Road, Andheri (E), Mumbai – 400059, MS – India.
http://inventiconasia.com/
AGGENDA
////////
P7435
Piramal Enterprises Mumbai, India
P-7435; P7435-DGAT1, P7435, P 7435
| Latest Stage of Development | Phase I |
| Standard Indication | Metabolic (unspecified) |
| Indication Details | Treat metabolic disorders |
https://clinicaltrials.gov/ct2/show/NCT01910571
https://clinicaltrials.gov/ct2/show/NCT01764425
Chairman Ajay Piramal
Nandini Piramal, Executive Director, Piramal Enterprises
http://www.pharmabiz.com/NewsDetails.aspx?aid=76992&sid=2
Our Bureau, Mumbai
Tuesday, August 06, 2013, 12:25 Hrs [IST]
Piramal Enterprises Ltd has received US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) P7435. This is a novel, potent and highly selective, oral diacylglycerolacyltransferase 1 (DGAT1) inhibitor.
P7435 has been developed by the NCE Research Division of PEL for the management of metabolic disorders such as lipid abnormalities and diabetes. It is well-established that increased lipid levels’ (including triglycerides) is one of the major risk factors for cardiovascular disease (CVD). It has been reported by the World Health Organisation, that CVD, is the number one cause of deaths globally, representing approximately 30 per cent of all deaths. Currently, there is a significant medical need for effective and safe drugs for the management of lipid abnormalities and metabolic disorders.
P7435 has demonstrated its lipid lowering potential in various preclinical studies by showing significant reduction in triglyceride levels, glucose and insulin levels,and decrease in food intake and body weight gain -factors which are associated with lipid abnormalities and metabolic disorders.
PEL has established the safety and tolerability of P7435 in a phase I trial recently completed in India. This extension trial in the US will further evaluate the safety and efficacy of P7435 in a larger population.
Dr Swati Piramal, vice chairperson, Piramal Enterprises, said, “The NCE Research division of PEL continues its ambitious diabetes/metabolic disorders programme to discover and develop NCEs to fight against diseases like diabetes and lipid disorders. With P7435 we are looking at addressing a serious need for effective and well-tolerated drugs that treat lipid disorders, which are commonly associated with diabetes and CVDs. Expansion of this trial will allow testing this NCE in a wider population,which is critical to the development of this drug and will provide therapeutic solutions not just to India but also to the rest of the world.”
The NCE Research division of Piramal Enterprises focuses on the discovery and development of innovative small molecule medicines to improve the lives of patients suffering from cancer, metabolic disorders and inflammatory conditions. The key elements of its strategy include capitalizing on Piramal’s strengths, in particular the India advantage, and leveraging external partnerships to achieve high levels of R&D productivity. Piramal’s state-of-the-art Research Centre in Mumbai has comprehensive capabilities spanning target identification all the way through clinical development. Its robust pipeline, including 8 compounds in clinical development, bears testimony to its innovative and rigorous drug discovery process.
PAPER
European Journal of Medicinal Chemistry (2012), 54, 324-342
http://www.sciencedirect.com/science/article/pii/S0223523412003133
PATENT
WO 2010023609
http://www.google.co.in/patents/WO2010023609A1?cl=en
/////////Piramal Enterprises, Mumbai, India, P-7435, P7435-DGAT1, P7435, P 7435, GDAT1 inhibitor
O=C(O)[C@@H](NC(=O)c1cc(no1)c2ccc(cc2)Nc3nc4ccc(F)cc4s3)C(C)C
